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 Background: Bone marrow stromal stem cells (BMSCs) are non-hematopoietic, 
stromal cellsthat can differentiate into mesenchymal and other type of tissues. 
The BMSCs have properties that make them ideal candidates for tissue 
engineering. The present study aimed to investigate the effect of deferoxamine 
(DFO) on homing of bone marrow-derived mesenchymal stem cell, and to 
examine if DFO can increase migration and subsequent homing of mesenchymal 
stem cells (MSCs) in vitro. 
Methods: BMSCs were isolated from the long bones of NMARI rats through 
density gradientcentrifugation and adherent cell culture. Next, they were treated 
using DFO in Dulbecco’s modified eagle medium (DMEM) for 24 h. The 
expression of chemokine receptor 2 (CCR2) were assessed using RT-PCR. 
Results: BMSCs expressed CCR2 on a large proportion of cells. In DFO-treated 
BMSCs,expression of CCR2 (P<0.005) significantly increased compared to that 
in control groups. Elevation and up regulation of CCR2 in DFO-treated MSCs 
were observed. 
Conclusion: Preconditioning of BMSCs using DFO prior to transplantation could 
increasehoming of BMSCs through affecting some chemokine receptors as well 
as proteases involved and thus improve the efficacy of cell therapy. 
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Introduction 
Bone Marrow Stromal Stem Cells 
(BMSCs)are non-hematopoietic stromal cells 
capableof differentiating into and contributing 
to theregeneration of mesenchymal tissues, 
including bone, cartilage, muscle, ligament, 
tendon, adipose, and neuron and glial cells [1, 
2]. They can also express Chondrogenic 
phenotypes [3] and are able to differentiate 
into neural elements in vitro [4].  
MSCs are capable of expanding many-fold in 
culture and still keeping their growth and 
multilineage potentials. The previous studies 
have shown immunosuppressive properties for 
MSCs [5]. They are regarded as non-
immunogenic agents; therefore, transplantation 
of MSCs into an allogeneic host may not 
require immunosuppression [6]. These 
properties make MSCs ideal candidates for 
tissue engineering as well as cellular and gene 
therapy. More-over, MSCs are shown to be 
able to migrate into damaged or diseased 
tissues when transplanted systemically [7, 8], 
including ischemic brain [9, 10], infarcted 
myocardium [11], and injured lung [12], where 
they have proven clinical value. These studies 
suggest that MSCs possess migratory capacity, 
yet the mechanisms underlying the migration 
of these cells have remained unknown. 
Chemokine receptors and their ligands 
together with adhesion molecules play an 
important role in tissue-specific homing of 
leukocytes [13]; they have also been 
implicated in trafficking of 
hematopoieticprecursors into and through 
tissues [14]. Chemokine presented on 
endothelial cells trigger integrin activation and 
arrest of those leukocytes carrying the 
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corresponding receptors [15]. The 
extravasation of a leukocyte is tightly 
controlled by the range of chemokine receptors 
and adhesion molecules expressed on the 
leukocyte cell surface, which are known as the 
cell’s address code [16]. The literature review 
points the functional expression of various 
chemokine receptors on human MSCs [17-22]. 
The results of these studies are sometimes 
inconsistent and the full panel of chemokine 
receptors is overlooked in many of these 
studies. Furthermore, various adhesion 
molecules are known to be expressed on 
human MSCs; some of these may be 
functionally important in the adhesion of 
MSCs to the endothelium [23, 24]. In the 
present study, we demonstrated the functional 
presence of chemokine receptors on rat MSCs, 
and showed that their expression profile 
exhibited similarities to that of human MSCs. 
 
Patients and Methods 
 
Isolation and expansion of rat BMSCs 
Female NMARI rats (Razi Institute, Tehran, 
Iran), weighing 200-250 g, were housed under 
standard conditions; the experimental 
procedures were approved by the Ethics 
Committee for Laboratory Animals at Shahid 
Beheshti University of Medical Sciences, 
Tehran. Bone Marrow was shortly re-moved 
from the long bones and cells plated out in cell 
isolation media (DMEM (SIGMA, UK) with 
10% FBS) at 37°C, and 5% CO2. Nonadherent 
cells were then removed after 24 hours. Next, 
cells were replated after 4 weeks at 100 cells 
per cm2 in complete expansion media with 
10% FBS to expand BMSCs. Afterwards, cells 
were passaged and then replated at a density of 
approximately 2×10
3




For the purpose of membrane receptor 
expression, rat BM-SCs were analyzed using a 
three-step labeling procedure. The cells were 
incubated at 4°C for 30 minutes with the 
relevant primary anti-mouse antibodies. After 
washing, the cells were incubated along with a 
biotinylated anti-rat Ig, anti-mouse Ig, anti-
rabbit Ig or anti-goat Ig antibody, and then 
with Streptavidin-PE conjugate. Also, as a 
negative control, the cells were incubated with 
the same species isotype controls as the 
primary antibodies. For each analysis, a 
minimum of 10,000 events were recorded 
making use of a FAC Scan flow cytometer and 
then analyzed using Cell Quest software (BD 
Biosciences, UK). The antibodies used in the 
present study were as follows: anti-rat CCR2 
(1 in 200), and anti-mouse CD105 (all from R 
& D Systems, UK), CD45 (all from BD 
Pharmingen, UK), anti-muse CD105 FITC (1 
in 50), CD34 (1 in 100), CD45 (1 in 100) and 




For osteogenic differentiation, rat MSCs were 
incubated in CEM using ascorbate-2-
phosphate (88 ng/ml), dexametha-sone (10−8 
M, Sigma-Aldrich, UK), and β-
glycerophosphate (10 mM, Sigma-Aldrich) 
and for adipogenic differentiation, MSCs were 
incubated in CEM using ITS (Insulin, 
Transfer-rin, Selenium), Premix (Gibco, UK), 
dexamethasone (10−6 M), 3-isobutyl-1-
methylxanthine (0.5 µM, Sigma-Aldrich), and 
indomethacin (100 µM, Sigma-Aldrich). After 
three weeks, cells were fixed and stained using 
Fast Red TR/naph-thol (Sigma-Aldrich) for 
alkaline phosphatase activity (osteoblastic 
differentiation), or using Oil Red O for 
adipogenic differentiation [25]. 
 
RT-PCR 
To check the expression of Oct-4, 
glyceraldehyde 3-phos-phate dehydrogenase 
(GAPDH), and CCR2 genes, the BMSC at the 
end of the fourth passage and treated cells 
were evaluated by DFO. Making use of the 
RNX plus Kit (Fer-mentas Inc., Maryland, 
USA), 2 µg of total RNA was treatedfrom 
each sample with DNase I (Fermentas Inc., 
Maryland, USA). The extracted RNA was 
evaluated for the purity and integrity by 
optical density measurements and 
electrophore-sis on 1% agarose gel. The First 
Strand cDNA Synthesis Kit (Ferments Inc. 
Maryland, USA) was used to convert the ex-
tracted RNA (1 µg) to cDNA. A total of 50 ng 
of cDNA was added to the PCR reaction for 
35 cycles with denaturation at 95°C for 45 
seconds, annealing at 58°C for 45 seconds, and 
elongation at 72°C for 30 seconds. After 
amplification was performed, the products 
were separated on 2% agarose gel and 
visualized making use of ethidium bromide 
under UV light. To ensure reproducibility, 
each experiment was repeat-ed for a minimum 
of 3 times [26]. 
 




Data were analyzed running 1-way analysis of 
variance (ANOVA), Turkey test, and 
Student’s t test. 
 
Results 
After the fourth passage of the isolated BMSC 
from the rat bone marrow, the viability of the 
cells was 96.23 ± 1.18% (mean±SEM) (Figure 
1). The cellular phenotype was char-acterized 
by immunocytochemistry for fibronectin, 
CD90, and CD106. Assays were performed on 
primary cells from 
the fourth passages. All BMSC cultures were 
observed to be CD34−, CD45−, and CD105+ 
and demonstrated the po-tentials of osteogenic 
and adipogenic differentiation. The BMSCs 
were previously shown to differentiate along 
the osteogenic, adipogenic, and chondrogenic 
pathways as well as having 
immunosuppressive properties similar to those 





Figure 1. Morphology of BMSC and BMSC after treatment by defroxamine 
 
Figure 2. The expression of Oct-4, GAPDH, CCR2+DFO,CCR2-DFO from right to left. 
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Characterization of BMSCs using 
flowcytometry 
The cell surface expression of chemokine 
receptors 2 (CCR2) was assessed in BMSC 
cultures at the fourth pas-sage and DFO 
treated using flowcytometry as described. The 
cell surface expression of CCR2 was also 
assessed in BMSC cultures using flow 
cytometry. A high percentage of BMSCs 
treated by DFO (89±14%) were observed to 
express CCR2 on the cell surface. In addition, 
a smaller proportion of both BMSC cell types 




The results obtained from RT-PCR of 
GAPDH, Oct-4, and CCR2 revealed that 
CCR2 was expressed in induced cells, Oct-4 in 
BMSCs and BMSC-DFO, and GAPDH in All 
groups (Figure 2). 
 
Discussion 
An increasing number of recent studies have 
reported the functional expression of different 
chemokine receptors on human BMSCs [17-
22]; nevertheless, the reported results have 
been contradictory. BMSCs show a huge 
increase in proportion to the cells expressing 
chemokine receptors on their surface when 
removed with EDTA alone rather than trypsin; 
this fact indicates the sensitivity of some or 
possibly all chemokine receptors to trypsin 
digestion.Ample expression of CCR2 on 
human BMSCs was found in the current 
investigation, which is in accordance with the 
findings reported in several other studies [17, 
23], where chemotactic responses to CXCL12 
were shown, too. However, other studies have 
reported little or no expression of this receptor 
on BMSCs [24, 25], which may have been due 
to different use of trypsin or other 
experimental conditions. We have also 
demonstrated functional expression of CCR2 
on a large proportion of BMSCs and 
interestingly, expression of all these four 
receptors was demonstrated on a proportion of 
BMSCs. Other groups, too, demonstrated 
functional expression of one or more of these 
receptors on human MSCs [26-27].All these 
four receptors (CCR6, CCR9, CXCR3, and 
CXCR6) are shown to be involved in 
recruitment of immune cells to areas of 
inflammation. CCR6 is involved in mucosal 
humeral immunity and intestinal T cell homing 
[28], and it has recently been reported that 
Th17 cells expressing CCR6. 
are preferentially recruited to inflamed joints 
via its ligand CCL20 in an animal model of 
rheumatoid arthritis [29]. In other words, both 
CXCR3 and CXCR6 have also been im-
plicated in the recruitment of T cells to 
inflamed tissues in autoimmune arthritis [28], 
as well as other inflammatory conditions. 
CCR9 is known to be involved in homing of T 
cells and plasma cells to the intestine, playing 
a role in inflammatory diseases of the gut, 
such as Crohn’s disease [30]. 
Considering the known functions of these 
receptors in relation to recruitment and homing 
of immune cells to in-flamed tissues, it is 
reasonable to hypothesize that these re-ceptors 
may also be involved in the recruitment and 
homing of rat and human BMSCs to inflamed 
tissues, either to re-generate tissue or 
contribute in immunosuppressive activitySome 
differences were apparent between the spectra 
of chemokine receptors expressed by human 
and murineMSCs. CCR3, CCR5, CXCR4, and 
CXCR5 were present abundantly on human 
cells while only low levels of these receptors 
occur on murine cells. 
 
Conclusion: 
The present study reported that rat BMSCs 
demonstrate selective expression of functional 
chemokine receptors. Thus, these BMSCs 
would be a useful model to further study the 
role of particular chemokine receptors in in 
vivo models of disease and injury, for example 
in cell therapy. 
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